Page 18 - 《中国药房》2025年3期

434420. bined with systemic chemotherapy for the treatment of 81
[54] CHEN L T，SATOH T，RYU M H，et al. A phase 3 study cases of gastrointestinal malignant tumors complicated
of nivolumab in previously treated advanced gastric or with ascites[J]. Cancer Res Clin，2009，21（1）：52-53.
gastroesophageal junction cancer （ATTRACTION-2）：2- [63] 黄万中，蒋华，刘燕文，等. 多西紫杉醇腹腔灌注化疗治
year update data[J]. Gastric Cancer，2020，23（3）：510-519. 疗晚期胃癌Ⅱ期临床研究[J]. 现代肿瘤医学，2011，19
[55] SHITARA K，DOI T，DVORKIN M，et al. Trifluridine/ （5）：960-963.
tipiracil versus placebo in patients with heavily pretreated HUANG W Z，JIANG H，LIU Y W，et al. Phase Ⅱ trial of
metastatic gastric cancer （TAGS）：a randomised，double- Intraperitoneal chemotherapy with docetaxel in the treat‐
blind，placebo-controlled，phase 3 trial[J]. Lancet Oncol， ment of advanced gastric cancer[J]. J Mod Oncol，2011，19
2018，19（11）：1437-1448. （5）：960-963.
[56] PYRHÖNEN S，KUITUNEN T，NYANDOTO P，et al. [64] PRABHU A，MISHRA D，BRANDL A，et al. Gastric can‐
Randomised comparison of fluorouracil，epidoxorubicin cer with peritoneal metastasis：a comprehensive review of
and methotrexate （FEMTX） plus supportive care with current intraperitoneal treatment modalities[J]. Front On‐
supportive care alone in patients with non-resectable gas‐ col，2022，12：864647.
tric cancer[J]. Br J Cancer，1995，71（3）：587-591. [65] BONNOT P E，PIESSEN G，KEPENEKIAN V，et al. Cy‐
[57] VAN CUTSEM E，MOISEYENKO V M，TJULANDIN toreductive surgery with or without hyperthermic intra‐
S，et al. Phase Ⅲ study of docetaxel and cisplatin plus peritoneal chemotherapy for gastric cancer with peritoneal
fluorouracil compared with cisplatin and fluorouracil as metastases （CYTO-CHIP study）：a propensity score
first-line therapy for advanced gastric cancer：a report of analysis[J]. J Clin Oncol，2019，37（23）：2028-2040.
the V325 study group[J]. J Clin Oncol，2006，24（31）： [66] ISHIGAMI H，KITAYAMA J，KAISAKI S，et al. Phase
4991-4997. Ⅱ study of weekly intravenous and intraperitoneal pacli‐
[58] KOIZUMI W，NARAHARA H，HARA T，et al. S-1 plus taxel combined with S-1 for advanced gastric cancer with
cisplatin versus S-1 alone for first-line treatment of ad‐ peritoneal metastasis[J]. Ann Oncol，2010，21（1）：67-70.
vanced gastric cancer （SPIRITS trial）：a phase Ⅲ trial[J]. [67] JIANG L X，LI P，GONG Z H，et al. Effective treatment
Lancet Oncol，2008，9（3）：215-221. for malignant pleural effusion and ascites with combined
[59] YAMAD Y，HIGUCHI K，NISHIKAWA K，et al. Phase therapy of bevacizumab and cisplatin[J]. Anticancer Res，
Ⅲ study comparing oxaliplatin plus S-1 with cisplatin 2016，36（3）：1313-1318.
plus S-1 in chemotherapy-naïve patients with advanced [68] ZHANG Y L，QIAN L，CHEN K，et al. Oncolytic adeno‐
gastric cancer[J]. Ann Oncol，2015，26（1）：141-148. virus in treating malignant ascites：a phase Ⅱ trial and lon‐
[60] COCCOLINI F，CATENA F，GLEHEN O，et al. Effect of gitudinal single-cell study[J]. Mol Ther，2024，32（6）：
intraperitoneal chemotherapy and peritoneal lavage in 2000-2020.
positive peritoneal cytology in gastric cancer：systematic [69] WANG J Q，DU L Y，CHEN X J. Oncolytic virus：a cata‐
review and meta-analysis[J]. Eur J Surg Oncol，2016，42 lyst for the treatment of gastric cancer[J]. Front Oncol，
（9）：1261-1267. 2022，12：1017692.
[61] ISHIGAMI H，FUJIWARA Y，FUKUSHIMA R，et al. [70] 樊代明 . 中国肿瘤整合诊治指南（CACA）：2022：胃癌
Phase Ⅲ trial comparing intraperitoneal and intravenous [M]. 天津：天津科学技术出版社，2022：919.
paclitaxel plus S-1 versus cisplatin plus S-1 in patients FAN D M. Guidelines for integrated diagnosis and treat‐
with gastric cancer with peritoneal metastasis：PHOENIX- ment of tumors in China（CACA）：2022：gastric cancer
GC trial[J]. J Clin Oncol，2018，36（19）：1922-1929. [M]. Tianjin：Tianjin Science and Technology Press，
[62] 李燕，李洁，张晓东，等. 腹腔联合全身化疗治疗胃肠道 2022：919.
恶性肿瘤并发腹腔积液 81 例[J]. 肿瘤研究与临床， （收稿日期：2024-11-03 修回日期：2024-12-23）
2009，21（1）：52-53. （编辑：刘明伟）
LI Y，LI J，ZHANG X D，et al. Abdominal cavity com‐

· 268 · China Pharmacy 2025 Vol. 36 No. 3 中国药房 2025年第36卷第3期